HemaCare second quarter revenue increases to $4.2 million

HemaCare Corporation (OTCBB:HEMA) announced today that the Company generated 2011 second quarter revenue of $4.2 million from continuing operations and a net loss of $252,000, or $(0.03)/share, including net income from discontinued operations of $180,000 compared to second quarter 2010 revenue from continuing operations of $3.9 million and net income of $223,000, or $.02/share, including net income of $843,000 from discontinued operations.

The Company generated 2011 year to date revenue of $8.1 million from continuing operations and a net loss of $642,000, or $(0.07)/share, including net income from discontinued operations of $285,000 compared to 2010 year to date revenue for continuing operations of $7.6 million and net income of $20,000, or $0.00/share, including net income of $1,595,000 from discontinued operations.

Commenting on the results, HemaCare's Chief Executive Officer, Pete van der Wal, stated, "Our second quarter results include certain discontinued operations which we sold to American Red Cross in July of this year. We continue to believe that our remaining operations hold greater promise for profitable growth, and expect to judiciously employ part of the net cash gain of approximately $1.7 million from the July transaction to bolster our growth prospects."

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.